Eli Lilly and Co Company Profile (NYSE:LLY)

About Eli Lilly and Co (LLY)

Eli Lilly and Co logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company's animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: LLY
  • CUSIP: 53245710
Key Metrics:
  • Previous Close: $84.36
  • 50 Day Moving Average: $81.21
  • 200 Day Moving Average: $77.16
  • 52-Week Range: $1,050,875,000.00 - $64.18
  • Trailing P/E Ratio: 32.70
  • Foreward P/E Ratio: 19.26
  • P/E Growth: 1.66
  • Market Cap: $88.65B
  • Outstanding Shares: 1,050,875,000
  • Beta: 0.3
  • Net Margins: 12.90%
  • Return on Equity: 24.74%
  • Return on Assets: 10.30%
  • Debt-to-Equity Ratio: 0.56%
  • Current Ratio: 1.62%
  • Quick Ratio: 1.15%

Analyst Ratings

Consensus Ratings for Eli Lilly and Co (NYSE:LLY) (?)
Ratings Breakdown: 3 Hold Ratings, 11 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.87)
Consensus Price Target: $87.82 (4.10% upside)

Analysts' Ratings History for Eli Lilly and Co (NYSE:LLY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/21/2017Credit Suisse Group AGReiterated RatingBuyLowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
3/11/2017Jefferies Group LLCReiterated RatingBuy$95.00 -> $97.00N/AView Rating Details
2/1/2017Barclays PLCBoost Price TargetBuy$80.00 -> $85.00N/AView Rating Details
2/1/2017BMO Capital MarketsReiterated RatingMarket Perform$70.00 -> $73.00N/AView Rating Details
1/19/2017Citigroup IncSet Price TargetBuy$100.00N/AView Rating Details
1/18/2017Goldman Sachs Group IncReiterated RatingConviction-Buy$92.00N/AView Rating Details
12/16/2016Morgan StanleyUpgradeEqual Weight -> Overweight$73.00 -> $82.00N/AView Rating Details
12/7/2016Sanford C. BernsteinReiterated RatingOverweightN/AView Rating Details
11/26/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
9/20/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
8/2/2016ArgusBoost Price TargetBuy$90.00 -> $95.00N/AView Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
2/4/2016Berenberg BankBoost Price TargetBuy$105.00 -> $106.00N/AView Rating Details
12/22/2015Bank of America CorpReiterated RatingBuy$104.00 -> $108.00N/AView Rating Details
12/9/2015Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
8/21/2015Cowen and CompanyReiterated RatingOutperform$92.00N/AView Rating Details
(Data available from 3/22/2015 forward)


Earnings History for Eli Lilly and Co (NYSE:LLY)
Earnings by Quarter for Eli Lilly and Co (NYSE:LLY)
Earnings History by Quarter for Eli Lilly and Co (NYSE:LLY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.67$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.65$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Eli Lilly and Co (NYSE:LLY)
Current Year EPS Consensus Estimate: $4.10 EPS
Next Year EPS Consensus Estimate: $4.38 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.80$0.86$0.83
Q2 20163$0.85$0.88$0.86
Q3 20163$0.90$0.98$0.93
Q4 20162$0.92$0.99$0.96
Q1 20171$0.98$0.98$0.98
Q2 20171$1.05$1.05$1.05
Q3 20171$1.04$1.04$1.04
Q4 20171$1.02$1.02$1.02
(Data provided by Zacks Investment Research)


Current Dividend Information for Eli Lilly and Co (NYSE:LLY)
Most Recent Dividend:3/10/2017
Annual Dividend:$2.08
Dividend Yield:2.47%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:80.62% (Trailing 12 Months of Earnings)
50.73% (Based on This Year's Estimates)
47.49% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Eli Lilly and Co (NYSE:LLY)

Dividend History by Quarter for Eli Lilly and Co (NYSE:LLY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Eli Lilly and Co (NYSE:LLY)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.15%
Insider Trades by Quarter for Eli Lilly and Co (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and Co (NYSE:LLY)
Insider Trades by Quarter for Eli Lilly and Co (NYSE:LLY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Eli Lilly and Co (NYSE:LLY)
Latest Headlines for Eli Lilly and Co (NYSE:LLY)
us.rd.yahoo.com logoBlog Coverage Eli Lilly Announced Positive Results from Breast Cancer Drug Combination Study (NYSE:LLY)
us.rd.yahoo.com - March 22 at 9:37 AM
seekingalpha.com logoEli Lilly and Company (LLY) (NYSE:LLY)
seekingalpha.com - March 21 at 11:19 PM
finance.yahoo.com logoLilly's Breast Cancer Combo Drug Phase III Results Positive (NYSE:LLY)
finance.yahoo.com - March 21 at 12:00 PM
wsj.com logoSunlight Is the Best Medicine for Pharma (NYSE:LLY)
www.wsj.com - March 21 at 6:37 AM
investopedia.com logoEli Lilly Breast Cancer Combo Succeeds (LLY,PFE) (NYSE:LLY)
www.investopedia.com - March 20 at 4:32 PM
wsj.com logo[$$] Sunlight Is the Best Medicine for Pharma (NYSE:LLY)
us.rd.yahoo.com - March 20 at 4:32 PM
us.rd.yahoo.com logoEli Lilly Breast Cancer Combo Does Well In Trial (NYSE:LLY)
us.rd.yahoo.com - March 20 at 4:32 PM
bloomberg.com logoEli Lilly Wants You to Know Its Price Hikes Don't Work (NYSE:LLY)
www.bloomberg.com - March 20 at 4:32 PM
News IconEli Lilly and Co (LLY) Receives Outperform Rating from Leerink Swann (NYSE:LLY)
www.americanbankingnews.com - March 20 at 3:40 PM
reuters.com logoBRIEF-Eli Lilly and Co says CEO John Lechleiter's 2016 total compensation was $18.4 mln (NYSE:LLY)
www.reuters.com - March 20 at 10:31 AM
us.rd.yahoo.com logoLilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival (NYSE:LLY)
us.rd.yahoo.com - March 20 at 10:31 AM
us.rd.yahoo.com logoLilly's breast cancer drug combination succeeds in key study (NYSE:LLY)
us.rd.yahoo.com - March 20 at 10:31 AM
seekingalpha.com logoIs Eli Lilly A Sell After Its 4-Month Run? (NYSE:LLY)
seekingalpha.com - March 17 at 6:30 PM
finance.yahoo.com logoFirst dedicated outcome trials of empagliflozin in chronic heart failure initiated (NYSE:LLY)
finance.yahoo.com - March 17 at 9:08 AM
bizjournals.com logoAratana: Osteoarthritis drug for dogs could be a 'blockbuster' (NYSE:LLY)
www.bizjournals.com - March 14 at 5:28 PM
fool.com logoBetter Buy: Eli Lilly and Company vs. Pfizer (NYSE:LLY)
us.rd.yahoo.com - March 13 at 6:04 PM
News IconEli Lilly and Co (LLY) Rating Reiterated by Jefferies Group LLC (NYSE:LLY)
www.americanbankingnews.com - March 11 at 2:23 PM
bizjournals.com logoWaltham-based Radius Health faces 3-month delay on drug approval (NYSE:LLY)
www.bizjournals.com - March 10 at 7:34 PM
seekingalpha.com logoEli Lilly and Company (LLY) Presents At Cowen and Company 37th Annual Health Care Conference (NYSE:LLY)
seekingalpha.com - March 8 at 7:04 PM
us.rd.yahoo.com logoEli Lilly's Taltz Shows Better Efficacy than J&J's Stelara (NYSE:LLY)
us.rd.yahoo.com - March 8 at 7:04 PM
latimes.com logoU.S. stocks open broadly lower (NYSE:LLY)
www.latimes.com - March 7 at 10:31 AM
us.rd.yahoo.com logo[$$] Graduates reveal the strengths and weaknesses of online MBAs (NYSE:LLY)
us.rd.yahoo.com - March 6 at 5:49 PM
finance.yahoo.com logo3:07 am Eli Lilly reports Taltz displays significantly higher response rates compared to Stelara in Moderate-to-Severe Plaque Psoriasis (NYSE:LLY)
finance.yahoo.com - March 6 at 8:43 AM
finance.yahoo.com logoNew Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis (NYSE:LLY)
finance.yahoo.com - March 4 at 6:28 PM
us.rd.yahoo.com logoLilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®' (NYSE:LLY)
us.rd.yahoo.com - March 3 at 6:15 PM
reuters.com logoBRIEF-Eli Lilly says senior VP of corporate affairs and communications to leave (NYSE:LLY)
www.reuters.com - March 2 at 11:35 PM
finance.yahoo.com logoLilly Announces Changes in Senior Management (NYSE:LLY)
finance.yahoo.com - March 2 at 10:17 AM
thestreet.com logoEli Lilly Announces Management Changes (NYSE:LLY)
www.thestreet.com - March 2 at 10:17 AM
bloomberg.com logoBig Pharma Is Losing a Fortune Trying to Cure Alzheimer's (NYSE:LLY)
www.bloomberg.com - March 1 at 5:59 PM
us.rd.yahoo.com logoLilly Completes Acquisition of CoLucid Pharmaceuticals (NYSE:LLY)
us.rd.yahoo.com - March 1 at 11:15 AM
us.rd.yahoo.com logo8:49 am Eli Lilly completes acquisition of CoLucid (CLCD (NYSE:LLY)
us.rd.yahoo.com - March 1 at 11:15 AM
us.rd.yahoo.com logoElanco, Eli Lilly & Co.’s Animal Health Segment (NYSE:LLY)
us.rd.yahoo.com - February 28 at 9:48 AM
finance.yahoo.com logoLilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting (NYSE:LLY)
finance.yahoo.com - February 28 at 9:48 AM
us.rd.yahoo.com logoEli Lilly & Co.’s Neuroscience Franchise (NYSE:LLY)
us.rd.yahoo.com - February 27 at 6:20 PM
us.rd.yahoo.com logoEli Lilly & Co.’s Oncology Franchise (NYSE:LLY)
us.rd.yahoo.com - February 27 at 6:20 PM
finance.yahoo.com logoLILLY ELI & CO Financials (NYSE:LLY)
finance.yahoo.com - February 25 at 5:58 PM


Frequently Asked Questions for Eli Lilly and Co (NYSE:LLY)

What is Eli Lilly and Co's stock symbol?

Eli Lilly and Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Co pay dividends? What is the dividend yield for Eli Lilly and Co?

Eli Lilly and Co declared a quarterly dividend on Tuesday, December 13th. Stockholders of record on Wednesday, February 15th will be paid a dividend of $0.52 per share on Friday, March 10th. This represents a $2.08 annualized dividend and a dividend yield of 2.47%. The ex-dividend date of this dividend is Monday, February 13th. This is an increase from Eli Lilly and Co's previous quarterly dividend of $0.51.

How were Eli Lilly and Co's earnings last quarter?

Eli Lilly and Co (NYSE:LLY) announced its quarterly earnings results on Tuesday, January, 31st. The company reported $0.95 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.98 by $0.03. The business earned $5.76 billion during the quarter, compared to analyst estimates of $5.54 billion. Eli Lilly and Co had a net margin of 12.90% and a return on equity of 24.74%. The business's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.78 earnings per share.

When will Eli Lilly and Co make its next earnings announcement?

Eli Lilly and Co is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

What guidance has Eli Lilly and Co issued on next quarter's earnings?

Eli Lilly and Co issued an update on its FY17 earnings guidance on Tuesday, January, 31st. The company provided earnings per share guidance of $4.05-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.09. The company issued revenue guidance of $21.8-22.3 billion, compared to the consensus revenue estimate of $21.98 billion.

Where is Eli Lilly and Co's stock going? Where will Eli Lilly and Co's stock price be in 2017?

15 equities research analysts have issued 1 year price targets for Eli Lilly and Co's shares. Their predictions range from $73.00 to $100.00. On average, they expect Eli Lilly and Co's stock price to reach $87.82 in the next year.

What are analysts saying about Eli Lilly and Co stock?

Here are some recent quotes from research analysts about Eli Lilly and Co stock:

  • 1. According to Zacks Investment Research, "Lilly’s fourth-quarter results were mixed with earnings missing estimates but revenues beating the same.   Earnings jumped 22% year over year backed by strong diabetes sales. In 2017, while new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo are expected to see higher revenues, Lilly expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. Although the stock’s decline was sharper than the large cap pharma industry in 2016, it has done well in 2017. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets." (2/15/2017)
  • 2. JPMorgan Chase & Co. analysts commented, "While the FDA recommends both cognitive and function endpoints for Alzheimer's drug approvals, we would not be surprised to see a positive cognitive endpoint and a trend towards functional benefit ultimately being sufficient for approval," analyst Chris Schott wrote in a note.Outcomes And ProbabilitiesThe analyst sees more than 15 percent upside in the stock if EXP-3 study meets both primary and secondary endpoints, which he states are between a 10–20 percent probability.The analyst expects a more muted 10 percent upside if the study hits on its primary but only shows a trend on secondary endpoints (50–60 percent probability).Further, Schott predicts a 10 percent drop in stock if the study fails both endpoints (about 30 percent probability).Moreover, irrespective of the outcome of solanezumab, Schott sees a diverse range of new product opportunities supporting Eli Lilly's greater than 5 percent top-line growth target. Related Link: Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7The analyst forecast about 6 percent top-line growth through 2020, with about 5 percent excluding risk adjusted solanezumab sales.The analyst's sales growth target is also supported by a number of $1+ billion product opportunities such as Trulicity, Jardiance, Taltz, baricitinib and abemaciclib."In aggregate, we forecast recent/upcoming new product launches to generate $11.4 billion in sales by 2020," (9/8/2016)

Who owns Eli Lilly and Co stock?

Eli Lilly and Co's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.89%), Franklin Resources Inc. (3.24%), Norges Bank (0.85%), Janus Capital Management LLC (0.79%), Putnam Investments LLC (0.38%) and Asset Management One Co. Ltd. (0.16%). Company insiders that own Eli Lilly and Co stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, R David Hoover, Stephen F Fry and Susan Mahony.

Who sold Eli Lilly and Co stock? Who is selling Eli Lilly and Co stock?

Eli Lilly and Co's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management Inc., Putnam Investments LLC, Capital Guardian Trust Co., Janus Capital Management LLC, I.G. Investment Management LTD., Cadinha & Co. LLC and Gabelli Funds LLC. Company insiders that have sold Eli Lilly and Co stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes and Susan Mahony.

Who bought Eli Lilly and Co stock? Who is buying Eli Lilly and Co stock?

Eli Lilly and Co's stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Franklin Resources Inc., State Street Corp, Asset Management One Co. Ltd., Alyeska Investment Group L.P., Russell Investments Group Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main and Renaissance Technologies LLC. Company insiders that have bought Eli Lilly and Co stock in the last two years include Jackson P Tai and R David Hoover.

How do I buy Eli Lilly and Co stock?

Shares of Eli Lilly and Co can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Eli Lilly and Co stock cost?

One share of Eli Lilly and Co stock can currently be purchased for approximately $84.36.

Eli Lilly and Co (LLY) Chart for Wednesday, March, 22, 2017

This page was last updated on 3/22/2017 by MarketBeat.com Staff